Article

 

Extended-release Naltrexone for Alcohol and Opioid Dependence : A Meta-Analysis of Healthcare Utilization Studies Public Deposited

Downloadable Content

Download PDF
https://ir.library.oregonstate.edu/concern/articles/mk61rj63x

Descriptions

Attribute NameValues
Creator
Abstract
  • Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX) may provide an advantage over other oral agents approved for alcohol and opioid dependence treatment. The objective of this study was to evaluate cost and utilization outcomes between XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence. Published studies were identified through comprehensive search of two electronic databases. Studies were included if they compared XR-NTX to other approved medicines and reported economic and healthcare utilization outcomes in patients with opioid or alcohol dependence. We identified five observational studies comparing 1,565 patients using XR-NTX to other therapies over six months. Alcohol dependent XR-NTX patients had longer medication refill persistence versus acamprosate and oral naltrexone. Healthcare utilization and costs was generally lower or as low for XR-NTX-treated patients relative to other alcohol dependence agents. Opioid dependent XR-NTX patients had lower inpatient substance abuse-related utilization versus other agents and $8170 lower total cost versus methadone.
Resource Type
DOI
Date Available
Date Issued
Citation
  • Hartung, D. M., McCarty, D., Fu, R., Wiest, K., Chalk, M. & Gastfriend, D. R. (2014). Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies. Journal of Substance Abuse Treatment, 47(2), 113-121. doi: 10.1016/j.jsat.2014.03.007
Journal Title
Journal Volume
  • 42
Journal Issue/Number
  • 7
Rights Statement
Funding Statement (additional comments about funding)
  • At the time this work was completed, Daniel Hartung had career development award (1K12HS019456) provided through the Oregon Comparative Effectiveness Research K12 Program from the Agency for Healthcare Research and Quality. Dennis McCarty also has support from a Research Services Agreement from Purdue Pharma and awards from the National Institute on Drug Abuse (U10 DA015815, P50 DA018165, R01 DA029716, R21 DA035640).
Publisher
Peer Reviewed
Language
Replaces
Additional Information
  • description.provenance : Made available in DSpace on 2014-04-18T23:52:15Z (GMT). No. of bitstreams: 1HartungPharmacyExtendedReleaseNaltrexone.pdf: 1451333 bytes, checksum: 896d89f238d704398a84ecb198ad212d (MD5) Previous issue date: 2014
  • description.provenance : Submitted by Sue Kunda (sue.kunda@oregonstate.edu) on 2014-04-18T23:51:38ZNo. of bitstreams: 1HartungPharmacyExtendedReleaseNaltrexone.pdf: 1451333 bytes, checksum: 896d89f238d704398a84ecb198ad212d (MD5)
  • description.provenance : Approved for entry into archive by Sue Kunda(sue.kunda@oregonstate.edu) on 2014-04-18T23:52:14Z (GMT) No. of bitstreams: 1HartungPharmacyExtendedReleaseNaltrexone.pdf: 1451333 bytes, checksum: 896d89f238d704398a84ecb198ad212d (MD5)

Relationships

Parents:

This work has no parents.

Items